| Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. | |
| | |
MedLine Citation:
|
PMID: 17278974 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Arterial stiffening and endothelial dysfunction are hallmarks of aging, and advanced glycation endproducts (AGE) may contribute to these changes. We tested the hypothesis that AGE crosslink breakers enhance endothelial flow-mediated dilation (FMD) in humans and examined the potential mechanisms for this effect. METHODS: Thirteen adults (nine men, aged 65 +/- 2 years) with isolated systolic hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure < 90 mmHg or pulse pressure > 60 mmHg) on stable antihypertensive therapy were studied. Subjects received placebo (2 weeks) then oral alagebrium (ALT-711; 210 mg twice a day for 8 weeks). Subjects and data analyses were blinded to treatment. Arterial stiffness was assessed by carotid augmentation index (AI) and brachial artery distensibility (ArtD) using applanation tonometry and Doppler echo, and endothelial function by brachial FMD. Serum markers of collagen metabolism and vascular inflammation were assessed. RESULTS: Alagebrium reduced carotid AI by 37% (P = 0.007) and augmented pressure (16.4 +/- 10 to 9.6 +/- 9 mmHg; P < 0.001). Heart rate, arterial pressures, and ArtD, were unchanged. FMD increased from 4.6 +/- 1.1 to 7.1 +/- 1.1% with alagebrium (P < 0.05), and was unrelated to altered shear stress or regional arterial distensibility. However, FMD change was inversely related to markers of collagen synthesis, p-selectin and intracellular cell adhesion molecule (all P < 0.05). Alagebrium-associated changes in plasma nitrite plus nitrate was inversely correlated with plasma matrix metalloproteinase 9 and type I collagen (P = 0.007). CONCLUSIONS: Alagebrium enhances peripheral artery endothelial function and improves overall impedance matching. Improved endothelial function correlates better with reduced vascular fibrosis and inflammation markers than with vessel distensibility. AGE-crosslink breakers may reduce cardiovascular risk in older adults by reduced central arterial stiffness and vascular remodeling. |
| | |
Authors:
|
Susan J Zieman; Vojtech Melenovsky; Lia Clattenburg; Mary C Corretti; Anne Capriotti; Gary Gerstenblith; David A Kass |
Related Documents
:
|
7998684 - Simple and accurate way for estimating total and segmental arterial compliance: the pul... 1553184 - R-pulse wave timing in cardiovascular monitoring: further observations. 10706324 - Epidemiological aspects of pulse pressure and arterial stiffness. 2269654 - Plotting systolic, diastolic, and pulse pressure on a real time scale. 7835524 - Radiological and histological analysis of the structural changes in the rat parotid gla... 19345364 - The role of ventilation frequency in airway reopening. |
Publication Detail:
|
Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of hypertension Volume: 25 ISSN: 0263-6352 ISO Abbreviation: J. Hypertens. Publication Date: 2007 Mar |
Date Detail:
|
Created Date: 2007-02-06 Completed Date: 2007-03-15 Revised Date: 2007-12-03 |
Medline Journal Info:
|
Nlm Unique ID: 8306882 Medline TA: J Hypertens Country: England |
Other Details:
|
Languages: eng Pagination: 577-83 Citation Subset: IM |
Affiliation:
|
Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. azieman@jhmi.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aging / physiology Blood Pressure / drug effects* Carotid Arteries / drug effects Collagen / biosynthesis, drug effects Elasticity / drug effects Endothelium, Vascular / drug effects, physiology Female Glycosylation End Products, Advanced / antagonists & inhibitors* Humans Hypertension / drug therapy, physiopathology Intercellular Adhesion Molecule-1 / blood Male Manometry Matrix Metalloproteinase 9 / blood Middle Aged Peripheral Vascular Diseases / drug therapy*, physiopathology Single-Blind Method Thiazoles / pharmacology* Transforming Growth Factor beta1 / blood Vascular Cell Adhesion Molecule-1 / blood Vasodilation / drug effects*, physiology |
| Grant Support | |
ID/Acronym/Agency:
|
1K23HL073059/HL/NHLBI NIH HHS; AG-18324/AG/NIA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/ALT 711; 0/Glycosylation End Products, Advanced; 0/Thiazoles; 0/Transforming Growth Factor beta1; 0/Vascular Cell Adhesion Molecule-1; 126547-89-5/Intercellular Adhesion Molecule-1; 9007-34-5/Collagen; EC 3.4.24.35/Matrix Metalloproteinase 9 |
| Comments/Corrections | |
Comment In:
|
J Hypertens. 2007 Mar;25(3):509-10
[PMID:
17278963
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Small artery elasticity assessed by pulse wave analysis is no measure of endothelial dysfunction.
Next Document: Increased arterial stiffness in remote Indigenous Australians with high risk of cardiovascular disea...